Drug Safety Meta-Analyses: US FDA Emphasizes Trial Quality Over Quantity
Executive Summary
Three years overdue, agency draft guidance seeks to inject a threshold level of rigor into meta-analyses of randomized, controlled trials to evaluate drug safety and proposes a three-tiered hierarchy of evidence against which FDA will evaluate such studies for regulatory decision-making purposes.
You may also be interested in...
The Meta-Physics Of Meta-Analysis: US FDA’s Curious Framing Of New Safety Guidance
Long delayed guidance on meta-analysis “will assist sponsors of drug and biological products in designing safety meta-analyses of randomized controlled trials using best practices,” FDA Commissioner says. True – but is that really the point?
Meta-Analyses After Avandia: FDA Hopes To Set Standards And Controls
FDA is working on a guidance for meta-analysis to support safety reviews, and it clearly hopes to have an impact beyond the walls of White Oak.
FDA Polled Review Staff On Avandia REMS Changes
Decision to replace the rosiglitazone REMS’ distribution restrictions with prescriber training reflected a consensus opinion shared by leadership in three CDER offices, despite a poll of reviewers who participated in a June advisory committee meeting and favored eliminating the risk management program.